Emerging Cancer

Description:

Okay, so I got hit bad by Dendreon, but who didn't? It was worth it to take a chance, especially after the surprisingly positive AC recommendation. But hindsight is 20/20, and I was blinded by message board contributors who didn't see the writing on the wall that pointed towards an approvable letter. But all is not lost if you are a true DNDN long as I still believe that the therapy has potential, and the experience has opened me up to the emerging cancer field, which even has it's own index fund in HHJ. This portfolio keeps track of all the stocks in this field, hopefully separating the wheat from the chaff.

Most Viewed Portfolios

View All

Articles

5 Stocks Insiders Love Right Now

07.30.14 | 11:35 AM

DELAFIELD, Wis. (Stockpickr) -- Corporate insiders sell their own companies' stock for a number of reasons. They might need the cash for a big pe...

Dividend Preview: 5 Stocks Ready to Pay You More

07.30.14 | 10:47 AM

BALTIMORE (Stockpickr) -- The S&P 500 may be pushing up against new all-time highs this month, but whatever you do, don't forget about dividends. ...

More Articles
blog comments powered by Disqus
brokerage partners
connect with Stockpickr
Fan us on FaceBook
Follow us on Twitter